{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:53:49Z","timestamp":1765886029381,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.breast.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T03:31:21Z","timestamp":1472441481000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population"],"prefix":"10.1016","volume":"30","author":[{"given":"S.","family":"Redana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Papadimitraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Capelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2016.07.019_bib1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/annonc\/mdn025","article-title":"Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations","volume":"19","author":"Hery","year":"2008","journal-title":"Ann Oncol"},{"issue":"9472","key":"10.1016\/j.breast.2016.07.019_bib2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"issue":"9814","key":"10.1016\/j.breast.2016.07.019_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.breast.2016.07.019_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"Prandoni","year":"2005","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2016.07.019_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(01)00619-2","article-title":"Cancer and the prothrombotic state","volume":"3","author":"Lip","year":"2002","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2016.07.019_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"7\u20138","key":"10.1016\/j.breast.2016.07.019_bib7","first-page":"677","article-title":"Venous thrombosis during multimodal treatment of primary breast carcinoma","volume":"65","author":"Weiss","year":"1981","journal-title":"Cancer Treat Rep"},{"issue":"9","key":"10.1016\/j.breast.2016.07.019_bib8","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1200\/JCO.1996.14.9.2560","article-title":"Blood coagulation during adjuvant epirubicin\/cyclophosphamide chemotherapy in patients with primary operable breast cancer","volume":"14","author":"von Tempelhoff","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2016.07.019_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM198802183180703","article-title":"The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer","volume":"318","author":"Levine","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2016.07.019_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.breast.2010.09.001","article-title":"The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer","volume":"20","author":"Nolan","year":"2011","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.breast.2016.07.019_bib11","first-page":"2383","article-title":"Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome","volume":"31","author":"Kirwan","year":"2011","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.breast.2016.07.019_bib12","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.breast.2016.07.019_bib13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdr524","article-title":"Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the \u2018SENDO experience\u2019","volume":"23","author":"Mandala","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2016.07.019_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.breast.2016.07.019_bib15","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.breast.2016.07.019_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3747\/co.v18i3.751","article-title":"Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres","volume":"18","author":"Madarnas","year":"2011","journal-title":"Curr Oncol"},{"issue":"36","key":"10.1016\/j.breast.2016.07.019_bib17","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roche","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2016.07.019_bib18","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3747\/co.19.940","article-title":"Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study","volume":"19","author":"Rayson","year":"2012","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.breast.2016.07.019_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2010.10.001","article-title":"Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group","volume":"47","author":"Fraser","year":"2011","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.breast.2016.07.019_bib20","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.breast.2016.07.019_bib21","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1200\/JCO.2009.23.0508","article-title":"High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide","volume":"27","author":"Soong","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2016.07.019_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"7485","key":"10.1016\/j.breast.2016.07.019_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2016.07.019_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-11-131","article-title":"Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: a pooled analysis","volume":"11","author":"Loibl","year":"2011","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.breast.2016.07.019_bib25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B","volume":"90","author":"Budman","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.breast.2016.07.019_bib26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.breast.2016.07.019_bib27","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO clinical practice guidelines","volume":"21","author":"de Naurois","year":"2010","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"10.1016\/j.breast.2016.07.019_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000046583","article-title":"Epidemiology of thrombosis in cancer","volume":"106","author":"Rickles","year":"2001","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.breast.2016.07.019_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.07.019_bib30","article-title":"NSABP B-36: a randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer","volume":"75","author":"Jacobs","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2016.07.019_bib31","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdp354","article-title":"Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial","volume":"21","author":"Mandal\u00e0","year":"2010","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2016.07.019_bib32","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.breast.2016.07.019_bib33","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.breast.2016.07.019_bib34","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa052084","article-title":"Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer","volume":"355","author":"Poole","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9676","key":"10.1016\/j.breast.2016.07.019_bib35","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(09)60740-6","article-title":"Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial","volume":"373","author":"Ellis","year":"2009","journal-title":"Lancet"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616301291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616301291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:35:08Z","timestamp":1760776508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977616301291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":35,"alternative-id":["S0960977616301291"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2016.07.019","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}